# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001703057-26-000020
Filing Date
2026-04-29
Accepted
2026-04-29 14:07:23
Documents
17
Period of Report
2025-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | abcl-20260429.htm iXBRL | DEF 14A | 743424
3 |  | abcl-20260429_g1.jpg | GRAPHIC | 21340
4 |  | abcl-20260429_g2.jpg | GRAPHIC | 63283
5 |  | abcl-20260429_g3.jpg | GRAPHIC | 91184
6 |  | abcl-20260429_g4.jpg | GRAPHIC | 248078
7 |  | abcl-20260429_g5.jpg | GRAPHIC | 243020
| Complete submission text file | 0001703057-26-000020.txt |  | 2976685

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
2 | XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | abcl-20260429.xsd | EX-101.SCH | 918
20 | EXTRACTED XBRL INSTANCE DOCUMENT | abcl-20260429_htm.xml | XML | 152755

Mailing Address 150 W 4TH AVENUE VANCOUVER A1 V5Y 1G6
Business Address 150 W 4TH AVENUE VANCOUVER A1 V5Y 1G6 (604) 559-9005
AbCellera Biologics Inc. (Filer) CIK: 0001703057 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39781 | Film No.: 26913890
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)